Invention Grant
- Patent Title: Anti-ILT4 antibodies and antigen-binding fragments
-
Application No.: US17338597Application Date: 2021-06-03
-
Publication No.: US11897957B2Publication Date: 2024-02-13
- Inventor: Milan Blanusa , Barbara Joyce-Shaikh , Andrea Claudia Schuster , Kornelia Schultze , Luis A. Zuniga
- Applicant: Merck Sharp & Dohme LLC , Agenus Inc.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme LLC,Agenus Inc.
- Current Assignee: Merck Sharp & Dohme LLC,Agenus Inc.
- Current Assignee Address: US NJ Rahway; US MA Lexington
- Agent Nichole M. Valeyko; Alysia Finnegan
- The original application number of the division: US15945779 2018.04.05
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
Public/Granted literature
- US20220033496A1 ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS Public/Granted day:2022-02-03
Information query
